Fast Track Granted to HCV Drug PSI-7977 | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Newly Recognized Factor in Mother-to-Child Transmission of Hepatitis C

Back to News Homepage
Next

Milk Thistle Interferes With Hepatitis C Replication

Fast Track Granted to HCV Drug PSI-7977

The Editors at Hepatitis Central
August 24, 2010

Print this page

Combining antiviral activity with a barrier to resistance, Pharmasset Inc.’s Hepatitis C drug, PSI-7977, has received fast track status by the FDA.

Pharmasset, Inc. (VRUS)’s PSI-7977 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection

8/12/2010

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ — Pharmasset, Inc. (Nasdaq:VRUS – News) has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-7977 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1. Pharmasset expects to initiate a 12-week Phase 2b study of PSI-7977 in the fourth quarter of 2010.

Continue reading this entire article:
http://www.biospace.com/news_story.aspx?NewsEntityId=190768&Source=TopBreaking

No Comments - be the first!
Share
Share
Previous

Newly Recognized Factor in Mother-to-Child Transmission of Hepatitis C

Back to News Homepage
Next

Milk Thistle Interferes With Hepatitis C Replication

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.